Feasibility and performance of continuous glucose monitoring in hyperglycemia after lung transplantation.

Autor:	Munoz Pena JM; Division of Endocrinology, Diabetes & Metabolism, University of Florida, Gainesville, FL, United States., Algarra K; Division of Endocrinology, Diabetes & Metabolism, University of Florida, Gainesville, FL, United States., Kennedy H; Division of Endocrinology, Diabetes & Metabolism, University of Florida, Gainesville, FL, United States., Leong MC; Department of Biostatistics, University of Florida, Gainesville, FL, United States., Salloum RG; Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in transplantation [Front Transplant] 2024 Jan 04; Vol. 2, pp. 1282215. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2023).
DOI:	10.3389/frtra.2023.1282215
Abstrakt:	Background: Post-Transplant Diabetes Mellitus (PTDM) affects 20%-40% of lung transplant recipients within five years, impacting rejection, infection, cardiovascular events, and mortality. Continuous glucose monitoring (CGM) is used in diabetes but not well-studied in PTDM. Objective: This study assessed CGM performance in detecting hypoglycemia and hyperglycemia post-lung transplantation, compared to self-monitoring blood glucose. Methods: A prospective pilot study included 15 lung transplant patients (mean age 58.6 years; 53.3% men; 73.3% with pre-transplantation diabetes) managing hyperglycemia with insulin. Patients used a blinded CGM and self-monitored glucose for ten days. Data were categorized (% time in range, % high, % very high, % low, % very low) and compared using paired t-tests. Results: CGM showed superior hyperglycemia detection. Mean differences for "% very high", "% high", and "% high and % very high" were 7.12 (95% CI, 1.8-12.4), 11.1 (95% CI, 3.5-18.8), and 18.3 (95% CI: 7.37-29.24), respectively. No significant difference was found for "% low and % very low". All patients reported a positive CGM experience. Conclusion: CGM use post-lung transplantation seems feasible and offers advantages in detecting hyperglycemia and in optimizing glucose management. Study limitations include a small sample size, requiring larger studies to assess glycemic control, hypoglycemia detection, and transplant outcomes. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Munoz Pena, Algarra, Kennedy, Leong and Salloum.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu